Aclarion Inc

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.

Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration.

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. Executive Chairman, Jeff Thramann will be presenting an overview of the Company and providing a business update.

Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV

BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Sigurd Berven M.D., Chief of Spine Service, Orthopaedic Surgery at University of California at San Francisco will advise the company as a key opinion leader (KOL) nationally.

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

Presentation on Tuesday, October 25th at 9:00 AM PTBroomfield, Colorado--(Newsfile Corp. - October 12, 2022) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today that it will be presenting at the 15th annual Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel.

Aclarion To Present at The LD Micro Main Event XV

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major diagnostic void between MRI and provocative discography BROOMFIELD, CO / ACCESSWIRE / October 10, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), announced today their participation at the North American Spine Society (NASS) 37th Annual Meeting. Aclarion executives, Brent Ness and Ryan Bond, will be attending the NASS meeting with industry-leading physicians and attending the Case Presentation on the National Institute of Health's Helping to End Addiction Long-term Initiative (NIH HEAL), Wednesday, October 12th at 3PM CT.

Aclarion Announces Participation at the NASS 37th Annual Meeting

Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution BROOMFIELD, CO / ACCESSWIRE / October 3, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that John Keller M.D., Chief of Neurosurgery at University of Michigan Health-West and Neurosurgeon at Great Lakes Neurosurgical Associates in Grand Rapids, MI, will advise the company as a Key Opinion Leader (KOL) in the greater Michigan market.

John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain NociscanTM to be commercially active across seven participating major academic medical centers BROOMFIELD, CO / ACCESSWIRE / September 19, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial funded through the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM. BEST will enroll over 800 patients at 12 leading academic teaching institutions across the United States, with a subset of 200 undergoing advanced biomarker profiling, which includes Nociscan.

Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain

Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that Jeff Thramann, Executive Chairman, and Brent Ness, CEO, will be attending and presenting at the Q3 Virtual Investor Summit.

Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

Direct Digital Holdings

MSP Recovery Inc

Low float penny stocks to watch right now. The post 3 Low Float Penny Stocks To Watch After KSPN Stock Explodes 180% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Low Float Penny Stocks To Watch After KSPN Stock Explodes 180%

Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial clinical evaluations with 87% of patients treated at discs identified as painful by Nociscan continuing to show significant clinical improvements at a two-year follow-up BROOMFIELD, CO / ACCESSWIRE / July 20, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the launch of the Economic Value Analysis of Low back pain (EVAL) study; a rigorous healthcare economic study to assess the impact of the Nociscan solution on the cost of care for patients suffering from chronic low back pain (CLBP). The University of California at San Francisco and the Center for Disruptive Musculoskeletal Innovations (CDMI), which is funded by the National Science Foundation, is conducting the study using outcomes data from previously published clinical studies.

Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan

Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022 SAN MATEO, CA / ACCESSWIRE / June 22, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that the Company will be participating in the 17th Annual State of Spine Surgery Think Tank in Los Cabos, Mexico, June 22-25, 2022, where it will be presenting 2-year follow up data on its pivotal clinical trial published in the European Spine Journal in 2019. The company will also outline its schedule for release of an economic analysis report and initiation of future clinical studies aimed at establishing Nociscan as a standard of care for chronic low back pain.

Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain

News for Aclarion Inc Stock (ACON)